AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance

Fiscal Year 2023 Fourth Quarter Highlights

  • Net sales of $91.1 million increased 4.7% compared to the prior-year quarter
    • Med Tech net sales of $26.5 million increased 17.2%
    • Med Device net sales of $64.6 million increased 0.3%
  • Gross margin of 50.9% declined 250 basis points year over year
  • GAAP loss per share of $0.54, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023
  • Adjusted earnings per share of $0.02
  • Cash and cash equivalents at May 31, 2023 were $44.6 million
  • On June 8, 2023, the Company completed the sale of its Dialysis and BioSentry Tract Sealant System Biopsy businesses to Merit Medical Systems, Inc. for $100 million in cash
  • Subsequent to quarter end, the Company completed enrollment in its PRESERVE study for the treatment of prostate cancer with NanoKnife

Full-Year 2023 Highlights

  • Net sales of $338.8 million increased 7.1% year over year
  • Gross margin declined 100 basis points year over year to 51.4%
  • GAAP loss per share of $1.33, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023
  • Adjusted loss per share of $0.06

LATHAM, N.Y.--()--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2023, which ended May 31, 2023.

“AngioDynamics’ fourth quarter and fiscal year 2023 saw continued growth driven by our team’s commitment to innovation,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “Additionally, we recently took another significant step in our transformation by announcing the divestiture of our Dialysis and BioSentry Biopsy businesses, which strengthens our balance sheet and enables an even clearer focus on our high-growth Med Tech platforms. Looking ahead, we will continue to seek opportunities to further focus the portfolio in order to drive growth and margin expansion.”

Mr. Clemmer continued, “We are now two years into the three-year plan that we provided in July of 2021, and we are at or above our overall revenue growth targets, with our Med Tech segment continuing to comprise an increasing portion of our overall business. This bodes well for our future, and I’m excited about the differentiated products and clinical data that we will be bringing to market in fiscal year 2024 and beyond.”

Fourth Quarter 2023 Financial Results

Net sales for the fourth quarter of fiscal year 2023 were $91.1 million, an increase of 4.7% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company's net sales in the quarter.

Med Tech net sales were $26.5 million, a 17.2% increase from $22.6 million in the prior- year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Growth was driven by Auryon sales during the quarter of $11.8 million, which increased 22.0%, NanoKnife disposable sales of $4.6 million, representing an increase of 28.0% compared to the fourth quarter of fiscal 2022, and AlphaVac sales of $1.8 million, an increase of 86.9% over the prior year.

Med Device net sales were $64.6 million, an increase of 0.3% compared to $64.4 million in the prior-year period.

U.S. net sales in the fourth quarter of fiscal 2023 were $74.4 million, an increase of 1.0% from $73.7 million a year ago. International net sales were $16.6 million, an increase of 25.1%, compared to $13.3 million a year ago.

Gross margin for the fourth quarter of fiscal 2023 was 50.9%, a decrease of 250 basis points compared to the fourth quarter of fiscal 2022, but up sequentially from 50.2% in the third quarter. Gross margin for the Med Tech business was 64.7%, a decrease of 400 basis points from the fourth quarter of fiscal 2022. Gross margin for the Med Device business was 45.2%, a decrease of 280 basis points compared to the fourth quarter of fiscal 2022. Gross margin continued to be impacted by inflationary pressures including increased costs for labor and raw materials.

The Company recorded a net loss of $21.5 million, or a loss per share of $0.54, in the fourth quarter of fiscal 2023. This includes a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023. This goodwill impairment is described in more detail below. This compares to a net loss of $6.3 million, or a loss per share of $0.16, a year ago.

Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income for the fourth quarter of fiscal 2023 was $0.7 million, and adjusted earnings per share was $0.02, compared to adjusted net income of $0.3 million and adjusted earnings per share of $0.01 in the prior-year period.

Adjusted EBITDA in the fourth quarter of fiscal 2023, excluding the items shown in the reconciliation table below, was $7.9 million, compared to $6.2 million in the fourth quarter of fiscal 2022.

In the fourth quarter of fiscal 2023, the Company generated $16.0 million in operating cash, had capital expenditures of $1.1 million and $0.5 million in Auryon placement and evaluation units.

At May 31, 2023, the Company had $44.6 million in cash and cash equivalents compared to $30.1 million in cash and cash equivalents at February 28, 2023. The Company had $25.0 million outstanding under its revolving credit facility and $25.0 million outstanding under the delayed draw term loan at May 31, 2023, equal to the total amounts outstanding on February 28, 2023. Subsequent to quarter end, the Company used part of the proceeds from the divestiture of its Dialysis and BioSentry Tract Sealant System Biopsy businesses to extinguish its debt.

Full-Year 2023 Financial Results

For the twelve months ended May 31, 2023:

Net sales were $338.8 million, an increase of 7.1%, compared to $316.2 million for the same period a year ago.

Med Tech net sales were $96.7 million, a 22.8% increase from the prior year period. Med Device net sales were $242.1 million, an increase of 1.9% from the prior year period.

Gross margin declined by 100 basis points to 51.4% from 52.4% a year ago as positive impacts from productivity and the growth of the Med Tech business were more than offset by inflationary pressures including increased costs for labor and raw materials.

The Company's net loss from continuing operations was $52.4 million, or a loss per share of $1.33, compared to a net loss of $26.5 million, or a loss per share of $0.68, a year ago. This includes a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023. This goodwill impairment is described in more detail below.

Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss was $2.4 million, with adjusted loss per share of $0.06, compared to adjusted net loss of $0.2 million, or adjusted earnings per share of $0.00, a year ago.

Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $22.6 million, compared to $20.9 million for the same period a year ago.

Goodwill Impairment in Connection with Divestiture

The Dialysis and BioSentry Tract Sealant System Biopsy businesses that were divested subsequent to the Company’s fiscal year end, on June 8, 2023, were accounted for as “Held for Sale” as of May 31, 2023. As a result, the Company recorded a goodwill impairment during the fiscal fourth quarter ended May 31, 2023. The gain on the sale of these assets will be recorded in the Company’s first fiscal quarter ending August 31, 2023.

Pro Forma 2023 Performance

In addition to actual results, the tables accompanying this press release reflect pro forma results, which exclude the full-year impact of the Dialysis and BioSentry Tract Sealant System Biopsy businesses that were divested on June 8, 2023.

Fiscal Year 2024 Financial Guidance

The Company expects its fiscal year 2024 net sales to be in the range of $328 to $333 million, gross margin to be approximately 50% to 52% and adjusted loss per share in the range of $0.28 to $0.34. For comparison, pro forma revenue, gross margin, and adjusted loss per share for FY23 when excluding the assets divested to Merit Medical were $306.3 million, 50.5%, and $0.43, respectively.

Conference Call

The Company's management will host a conference call today at 8:00 a.m. ET to discuss its fourth quarter and fiscal year 2023 results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1- 201-689-8560 (international) and refer to the passcode 13739492.

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Wednesday, July 12, 2023, until 11:59 p.m. ET on Wednesday, July 19, 2023. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13739492.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," “projects”, "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2022. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(unaudited)

 

(audited)

 

 

 

 

 

 

 

 

Net sales

$

91,074

 

 

$

86,998

 

 

$

338,752

 

 

$

316,219

 

Cost of sales (exclusive of intangible amortization)

 

44,715

 

 

 

40,543

 

 

 

164,506

 

 

 

150,487

 

Gross profit

 

46,359

 

 

 

46,455

 

 

 

174,246

 

 

 

165,732

 

% of net sales

 

50.9

%

 

 

53.4

%

 

 

51.4

%

 

 

52.4

%

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

7,860

 

 

 

7,866

 

 

 

29,883

 

 

 

30,739

 

Sales and marketing

 

26,293

 

 

 

26,833

 

 

 

104,249

 

 

 

95,301

 

General and administrative

 

10,228

 

 

 

11,103

 

 

 

40,003

 

 

 

38,451

 

Amortization of intangibles

 

4,406

 

 

 

4,853

 

 

 

18,790

 

 

 

19,458

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

14,549

 

 

 

 

Change in fair value of contingent consideration

 

236

 

 

 

207

 

 

 

2,320

 

 

 

1,212

 

Acquisition, restructuring and other items, net

 

3,624

 

 

 

1,990

 

 

 

15,633

 

 

 

9,042

 

Total operating expenses

 

67,196

 

 

 

52,852

 

 

 

225,427

 

 

 

194,203

 

Operating loss

 

(20,837

)

 

 

(6,397

)

 

 

(51,181

)

 

 

(28,471

)

Interest expense, net

 

(901

)

 

 

(185

)

 

 

(2,702

)

 

 

(688

)

Other expense, net

 

(127

)

 

 

(139

)

 

 

(554

)

 

 

(790

)

Total other expense, net

 

(1,028

)

 

 

(324

)

 

 

(3,256

)

 

 

(1,478

)

Loss before income tax benefit

 

(21,865

)

 

 

(6,721

)

 

 

(54,437

)

 

 

(29,949

)

Income tax benefit

 

(398

)

 

 

(455

)

 

 

(1,995

)

 

 

(3,402

)

Net loss

$

(21,467

)

 

$

(6,266

)

 

$

(52,442

)

 

$

(26,547

)

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic

$

(0.54

)

 

$

(0.16

)

 

$

(1.33

)

 

$

(0.68

)

Diluted

$

(0.54

)

 

$

(0.16

)

 

$

(1.33

)

 

$

(0.68

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

 

39,608

 

 

 

39,160

 

 

 

39,480

 

 

 

39,009

 

Diluted

 

39,608

 

 

 

39,160

 

 

 

39,480

 

 

 

39,009

 

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

 
Reconciliation of Net Loss to non-GAAP Adjusted Net Loss Before Goodwill Impairment:

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(21,467

)

 

$

(6,266

)

 

$

(52,442

)

 

$

(26,547

)

Goodwill impairment

 

14,549

 

 

 

 

 

 

14,549

 

 

 

 

Net loss adjusted for goodwill impairment*

$

(6,918

)

 

$

(6,266

)

 

$

(37,893

)

 

$

(26,547

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Loss Per Share Before Goodwill Impairment:

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.54

)

 

$

(0.16

)

 

$

(1.33

)

 

$

(0.68

)

Goodwill impairment

 

0.37

 

 

 

 

 

 

0.37

 

 

 

 

Adjusted diluted loss per share adjusted for goodwill impairment*

$

(0.17

)

 

$

(0.16

)

 

$

(0.96

)

 

$

(0.68

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount

 

39,608

 

 

 

39,160

 

 

 

39,480

 

 

 

39,009

 

 

 

 

 

 

 

 

 

*This does not include the Company's customary adjustments included on the next page.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

 

Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(21,467

)

 

$

(6,266

)

 

$

(52,442

)

 

$

(26,547

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

4,406

 

 

 

4,853

 

 

 

18,790

 

 

 

19,458

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

14,549

 

 

 

 

Change in fair value of contingent consideration

 

236

 

 

 

207

 

 

 

2,320

 

 

 

1,212

 

Acquisition, restructuring and other items, net (1)

 

3,624

 

 

 

1,990

 

 

 

15,633

 

 

 

9,042

 

Tax effect of non-GAAP items (2)

 

(617

)

 

 

(531

)

 

 

(1,272

)

 

 

(3,347

)

Adjusted net income (loss)

$

731

 

 

$

253

 

 

$

(2,422

)

 

$

(182

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Earnings (Loss) Per Share:

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.54

)

 

$

(0.16

)

 

$

(1.33

)

 

$

(0.68

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.11

 

 

 

0.12

 

 

 

0.48

 

 

 

0.50

 

Goodwill impairment

 

0.37

 

 

 

 

 

 

0.37

 

 

 

 

Change in fair value of contingent consideration

 

0.01

 

 

 

0.01

 

 

 

0.06

 

 

 

0.03

 

Acquisition, restructuring and other items, net (1)

 

0.09

 

 

 

0.05

 

 

 

0.39

 

 

 

0.24

 

Tax effect of non-GAAP items (2)

 

(0.02

)

 

 

(0.01

)

 

 

(0.03

)

 

 

(0.09

)

Adjusted diluted earnings (loss) per share

$

0.02

 

 

$

0.01

 

 

$

(0.06

)

 

$

0.00

 

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

39,916

 

 

 

40,250

 

 

 

39,480

 

 

 

39,009

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2023 and May 31, 2022.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

 

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION (Continued)

(in thousands, except per share data)

 

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(21,467

)

 

$

(6,266

)

 

$

(52,442

)

 

$

(26,547

)

 

 

 

 

 

 

 

 

Income tax benefit

 

(398

)

 

 

(455

)

 

 

(1,995

)

 

 

(3,402

)

Interest expense, net

 

901

 

 

 

185

 

 

 

2,702

 

 

 

688

 

Depreciation and amortization

 

7,506

 

 

 

7,628

 

 

 

30,681

 

 

 

29,194

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

14,549

 

 

 

 

Change in fair value of contingent consideration

 

236

 

 

 

207

 

 

 

2,320

 

 

 

1,212

 

Stock based compensation

 

2,981

 

 

 

2,903

 

 

 

11,158

 

 

 

10,692

 

Acquisition, restructuring and other items, net (1)

 

3,624

 

 

 

1,990

 

 

 

15,633

 

 

 

9,042

 

Adjusted EBITDA

$

7,932

 

 

$

6,192

 

 

$

22,606

 

 

$

20,879

 

 

 

 

 

 

 

 

 

Per diluted share:

 

 

 

 

 

 

 

Adjusted EBITDA

$

0.20

 

 

$

0.15

 

 

$

0.57

 

 

$

0.54

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

(in thousands)

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31,
2023

 

May 31,
2022

 

%
Growth

 

Currency
Impact

 

Constant
Currency
Growth

 

May 31,
2023

 

May 31,
2022

 

%
Growth

 

Currency
Impact

 

Constant
Currency
Growth

 

 

 

 

 

 

 

 

 

 

 

(unaudited)

 

 

 

 

 

 

 

(unaudited)

 

 

 

 

 

 

Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Med Tech

$

26,494

 

$

22,611

 

17.2

%

 

 

 

 

 

$

96,687

 

$

78,717

 

22.8

%

 

 

 

 

Med Device

 

64,580

 

 

64,387

 

0.3

%

 

 

 

 

 

 

242,065

 

 

237,502

 

1.9

%

 

 

 

 

 

$

91,074

 

$

86,998

 

4.7

%

 

0.2

%

 

4.9

%

 

$

338,752

 

$

316,219

 

7.1

%

 

0.4

%

 

7.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales by Geography

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

$

74,439

 

$

73,704

 

1.0

%

 

 

 

 

 

$

282,713

 

$

265,963

 

6.3

%

 

 

 

 

International

 

16,635

 

 

13,294

 

25.1

%

 

1.1

%

 

26.2

%

 

 

56,039

 

 

50,256

 

11.5

%

 

2.5

%

 

14.0

%

 

$

91,074

 

$

86,998

 

4.7

%

 

0.2

%

 

4.9

%

 

$

338,752

 

$

316,219

 

7.1

%

 

0.4

%

 

7.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT BY PRODUCT CATEGORY

(in thousands)

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

% Change

 

May 31, 2023

 

May 31, 2022

 

% Change

 

(unaudited)

 

 

 

(unaudited)

 

 

Med Tech

$

17,150

 

 

$

15,524

 

 

10.5

%

 

$

61,966

 

 

$

52,584

 

 

17.8

%

Gross profit % of sales

 

64.7

%

 

 

68.7

%

 

 

 

 

64.1

%

 

 

66.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Med Device

$

29,209

 

 

$

30,931

 

 

(5.6

)%

 

$

112,280

 

 

$

113,148

 

 

(0.8

)%

Gross profit % of sales

 

45.2

%

 

 

48.0

%

 

 

 

 

46.4

%

 

 

47.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

$

46,359

 

 

$

46,455

 

 

(0.2

)%

 

$

174,246

 

 

$

165,732

 

 

5.1

%

Gross profit % of sales

 

50.9

%

 

 

53.4

%

 

 

 

 

51.4

%

 

 

52.4

%

 

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands)

 

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(audited)

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

44,620

 

$

28,825

Accounts receivable, net

 

52,826

 

 

52,304

Inventories

 

55,325

 

 

51,392

Prepaid expenses and other

 

4,617

 

 

10,824

Current assets held for sale

 

6,154

 

 

Total current assets

 

163,542

 

 

143,345

Property, plant and equipment, net

 

44,384

 

 

45,005

Other assets

 

10,676

 

 

10,963

Intangible assets, net

 

111,144

 

 

152,380

Goodwill

 

159,238

 

 

201,058

Non-current assets held for sale

 

43,653

 

 

Total assets

$

532,637

 

$

552,751

Liabilities and stockholders' equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

40,445

 

$

28,047

Accrued liabilities

 

26,617

 

 

34,842

Current portion of contingent consideration

 

14,761

 

 

8,783

Other current liabilities

 

2,002

 

 

2,652

Total current liabilities

 

83,825

 

 

74,324

Long-term debt, net of current portion

 

49,818

 

 

25,000

Deferred income taxes

 

12,813

 

 

16,037

Contingent consideration, net of current portion

 

4,535

 

 

8,165

Other long-term liabilities

 

3,350

 

 

4,736

Total liabilities

 

154,341

 

 

128,262

Stockholders' equity

 

378,296

 

 

424,489

Total Liabilities and Stockholders' Equity

$

532,637

 

$

552,751

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

 

Three Months Ended

 

Twelve Months Ended

 

May 31, 2023

 

May 31, 2022

 

May 31, 2023

 

May 31, 2022

 

(unaudited)

 

(unaudited)

 

(audited)

Cash flows from operating activities:

 

 

 

 

 

 

 

Net loss

$

(21,467

)

 

$

(6,266

)

 

$

(52,442

)

 

$

(26,547

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

7,557

 

 

 

7,667

 

 

 

30,873

 

 

 

29,349

 

Non-cash lease expense

 

601

 

 

 

617

 

 

 

2,484

 

 

 

2,439

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

14,549

 

 

 

 

Stock based compensation

 

2,981

 

 

 

2,903

 

 

 

11,158

 

 

 

10,692

 

Change in fair value of contingent consideration

 

236

 

 

 

207

 

 

 

2,320

 

 

 

1,212

 

Deferred income tax provision

 

(558

)

 

 

(587

)

 

 

(2,310

)

 

 

(3,708

)

Change in accounts receivable allowances

 

135

 

 

 

184

 

 

 

695

 

 

 

118

 

Asset impairments and disposals

 

147

 

 

 

146

 

 

 

291

 

 

 

391

 

Other

 

(197

)

 

 

(66

)

 

 

(514

)

 

 

(93

)

Changes in operating assets and liabilities, net of acquisitions:

 

 

 

 

 

 

 

Accounts receivable

 

(2,058

)

 

 

(10,710

)

 

 

(1,299

)

 

 

(17,151

)

Inventories

 

4,056

 

 

 

(3,384

)

 

 

(8,198

)

 

 

(2,796

)

Prepaid expenses and other

 

724

 

 

 

2,135

 

 

 

332

 

 

 

(5,012

)

Accounts payable, accrued and other liabilities

 

9,248

 

 

 

15,714

 

 

 

2,139

 

 

 

3,912

 

Net cash provided by (used in) operating activities

 

15,954

 

 

 

8,560

 

 

 

78

 

 

 

(7,194

)

Cash flows from investing activities:

 

 

 

 

 

 

 

Additions to property, plant and equipment

 

(1,056

)

 

 

(1,039

)

 

 

(3,812

)

 

 

(4,297

)

Additions to placement and evaluation units

 

(472

)

 

 

(2,734

)

 

 

(5,394

)

 

 

(11,410

)

Acquisition of intangibles

 

 

 

 

 

 

 

(540

)

 

 

 

Cash paid in acquisition

 

 

 

 

 

 

 

 

 

 

(3,600

)

Net cash used in investing activities

 

(1,528

)

 

 

(3,773

)

 

 

(9,746

)

 

 

(19,307

)

Cash flows from financing activities:

 

 

 

 

 

 

 

Proceeds from issuance of long-term debt

 

 

 

 

 

 

 

70,000

 

 

 

 

Repayment of long-term debt

 

 

 

 

 

 

 

(45,000

)

 

 

 

Proceeds from borrowings on long-term debt

 

 

 

 

 

 

 

 

 

 

5,000

 

Deferred financing costs on long-term debt

 

 

 

 

 

 

 

(751

)

 

 

 

Proceeds from exercise of stock options and employee stock purchase plan

 

 

 

 

329

 

 

 

1,171

 

 

 

2,683

 

Net cash provided by financing activities

 

 

 

 

329

 

 

 

25,420

 

 

 

7,683

 

Effect of exchange rate changes on cash and cash equivalents

 

83

 

 

 

(181

)

 

 

43

 

 

 

(518

)

Increase (decrease) in cash and cash equivalents

 

14,509

 

 

 

4,935

 

 

 

15,795

 

 

 

(19,336

)

Cash and cash equivalents at beginning of period

 

30,111

 

 

 

23,890

 

 

 

28,825

 

 

 

48,161

 

Cash and cash equivalents at end of period

$

44,620

 

 

$

28,825

 

 

$

44,620

 

 

$

28,825

 

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA CONSOLIDATED INCOME STATEMENTS

Three Months Ended August 31, 2022

(in thousands, except per share data)

 

 

As Reported (1)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net sales

$

81,537

 

 

$

(7,746

)

 

(2)

 

$

73,791

 

Cost of sales (exclusive of intangible amortization)

 

39,232

 

 

 

(3,108

)

 

(2)

 

 

36,124

 

Gross profit

 

42,305

 

 

 

(4,638

)

 

 

 

 

37,667

 

% of net sales

 

51.9

%

 

 

 

 

 

 

51.0

%

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

8,333

 

 

 

(62

)

 

(2)

 

 

8,271

 

Sales and marketing

 

26,543

 

 

 

(19

)

 

(2)

 

 

26,524

 

General and administrative

 

10,101

 

 

 

(1

)

 

(2)

 

 

10,100

 

Amortization of intangibles

 

4,837

 

 

 

(483

)

 

(2)

 

 

4,354

 

Change in fair value of contingent consideration

 

211

 

 

 

 

 

 

 

 

211

 

Acquisition, restructuring and other items, net

 

5,581

 

 

 

(17

)

 

(2)

 

 

5,564

 

Total operating expenses

 

55,606

 

 

 

(582

)

 

 

 

 

55,024

 

Operating loss

 

(13,301

)

 

 

(4,056

)

 

 

 

 

(17,357

)

Interest expense, net

 

(381

)

 

 

 

 

 

 

 

(381

)

Other expense, net

 

(175

)

 

 

 

 

 

 

 

(175

)

Total other expense, net

 

(556

)

 

 

 

 

 

 

 

(556

)

Loss before income tax benefit

 

(13,857

)

 

 

(4,056

)

 

 

 

 

(17,913

)

Income tax benefit

 

(853

)

 

 

 

 

(3)

 

 

(853

)

Net loss

$

(13,004

)

 

$

(4,056

)

 

 

 

$

(17,060

)

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic

$

(0.33

)

 

 

 

 

 

$

(0.43

)

Diluted

$

(0.33

)

 

 

 

 

 

$

(0.43

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

 

39,302

 

 

 

 

 

 

 

39,302

 

Diluted

 

39,302

 

 

 

 

 

 

 

39,302

 

(1) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Dialysis and BioSentry Biopsy Businesses ("the Business") for the three months ended August 31, 2022.

(2) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

(3) There are no adjustments for income tax expense or deferred taxes when considering valuation allowances on the Company's deferred taxes.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION

Three Months Ended August 31, 2022

(in thousands, except per share data)

 

Reconciliation of Net Loss to non-GAAP Adjusted Net Loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(13,004

)

 

$

(4,056

)

 

(5)

 

$

(17,060

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

4,837

 

 

 

(483

)

 

(5)

 

 

4,354

 

Change in fair value of contingent consideration

 

211

 

 

 

 

 

 

 

 

211

 

Acquisition, restructuring and other items, net (1)

 

5,581

 

 

 

(17

)

 

(5)

 

 

5,564

 

Tax effect of non-GAAP items (2)

 

(111

)

 

 

1,048

 

 

 

 

 

937

 

Adjusted net loss

$

(2,486

)

 

$

(3,508

)

 

 

 

$

(5,994

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Loss Per Share:

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.33

)

 

$

(0.11

)

 

(5)

 

$

(0.44

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.12

 

 

 

(0.01

)

 

(5)

 

 

0.11

 

Change in fair value of contingent consideration

 

0.01

 

 

 

 

 

 

 

 

0.01

 

Acquisition, restructuring and other items, net (1)

 

0.14

 

 

 

 

 

 

 

 

0.14

 

Tax effect of non-GAAP items (2)

 

 

 

 

0.03

 

 

 

 

 

0.03

 

Adjusted diluted loss per share

$

(0.06

)

 

$

(0.09

)

 

 

 

$

(0.15

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

39,302

 

 

 

 

 

 

 

39,302

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended August 31, 2022.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

(4) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended August 31, 2022.

(5) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)

Three Months Ended August 31, 2022

(in thousands, except per share data)

 

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (2)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(13,004

)

 

$

(4,056

)

 

(3)

 

$

(17,060

)

 

 

 

 

 

 

 

 

Income tax benefit

 

(853

)

 

 

 

 

 

 

 

(853

)

Interest expense, net

 

381

 

 

 

 

 

 

 

 

381

 

Depreciation and amortization

 

7,621

 

 

 

(490

)

 

(3)

 

 

7,131

 

Change in fair value of contingent consideration

 

211

 

 

 

 

 

 

 

 

211

 

Stock based compensation

 

3,024

 

 

 

 

 

 

 

 

3,024

 

Acquisition, restructuring and other items, net (1)

 

5,581

 

 

 

(17

)

 

(3)

 

 

5,564

 

Adjusted EBITDA

$

2,961

 

 

$

(4,563

)

 

 

 

$

(1,602

)

 

 

 

 

 

 

 

 

Per diluted share:

 

 

 

 

 

 

 

Adjusted EBITDA

$

0.08

 

 

$

(0.12

)

 

 

 

$

(0.04

)

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended August 31, 2022.

(3) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA CONSOLIDATED INCOME STATEMENTS

Three Months Ended November 30, 2022

(in thousands, except per share data)

 

 

As Reported (1)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net sales

$

85,429

 

 

$

(8,442

)

 

(2)

 

$

76,987

 

Cost of sales (exclusive of intangible amortization)

 

40,351

 

 

 

(3,184

)

 

(2)

 

 

37,167

 

Gross profit

 

45,078

 

 

 

(5,258

)

 

 

 

 

39,820

 

% of net sales

 

52.8

%

 

 

 

 

 

 

51.7

%

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

6,838

 

 

 

(66

)

 

(2)

 

 

6,772

 

Sales and marketing

 

26,007

 

 

 

(15

)

 

(2)

 

 

25,992

 

General and administrative

 

10,835

 

 

 

2

 

 

(2)

 

 

10,837

 

Amortization of intangibles

 

4,808

 

 

 

(483

)

 

(2)

 

 

4,325

 

Change in fair value of contingent consideration

 

1,646

 

 

 

 

 

 

 

 

1,646

 

Acquisition, restructuring and other items, net

 

3,059

 

 

 

 

 

 

 

 

3,059

 

Total operating expenses

 

53,193

 

 

 

(562

)

 

 

 

 

52,631

 

Operating loss

 

(8,115

)

 

 

(4,696

)

 

 

 

 

(12,811

)

Interest expense, net

 

(684

)

 

 

 

 

 

 

 

(684

)

Other expense, net

 

(252

)

 

 

 

 

 

 

 

(252

)

Total other expense, net

 

(936

)

 

 

 

 

 

 

 

(936

)

Loss before income tax benefit

 

(9,051

)

 

 

(4,696

)

 

 

 

 

(13,747

)

Income tax benefit

 

(565

)

 

 

 

 

(3)

 

 

(565

)

Net loss

$

(8,486

)

 

$

(4,696

)

 

 

 

$

(13,182

)

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic

$

(0.21

)

 

 

 

 

 

$

(0.33

)

Diluted

$

(0.21

)

 

 

 

 

 

$

(0.33

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

 

39,490

 

 

 

 

 

 

 

39,490

 

Diluted

 

39,490

 

 

 

 

 

 

 

39,490

 

(1) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended November 30, 2022.

(2) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

(3) There are no adjustments for income tax expense or deferred taxes when considering valuation allowances on the Company's deferred taxes.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION

Three Months Ended November 30, 2022

(in thousands, except per share data)

 

Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(8,486

)

 

$

(4,696

)

 

(5)

 

$

(13,182

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

4,808

 

 

 

(483

)

 

(5)

 

 

4,325

 

Change in fair value of contingent consideration

 

1,646

 

 

 

 

 

 

 

 

1,646

 

Acquisition, restructuring and other items, net (1)

 

3,059

 

 

 

 

 

 

 

 

3,059

 

Tax effect of non-GAAP items (2)

 

(671

)

 

 

1,191

 

 

 

 

 

520

 

Adjusted net income (loss)

$

356

 

 

$

(3,988

)

 

 

 

$

(3,632

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Earnings (Loss) Per Share:

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.21

)

 

$

(0.12

)

 

(5)

 

$

(0.33

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.12

 

 

 

(0.01

)

 

(5)

 

 

0.11

 

Change in fair value of contingent consideration

 

0.04

 

 

 

 

 

 

 

 

0.04

 

Acquisition, restructuring and other items, net (1)

 

0.08

 

 

 

 

 

 

 

 

0.08

 

Tax effect of non-GAAP items (2)

 

(0.02

)

 

 

0.03

 

 

 

 

 

0.01

 

Adjusted diluted earnings (loss) per share

$

0.01

 

 

$

(0.10

)

 

 

 

$

(0.09

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

40,059

 

 

 

 

 

 

 

39,490

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended November 30, 2022.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

(4) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended November 30, 2022.

(5) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)

Three Months Ended November 30, 2022

(in thousands, except per share data)

 

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (2)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(8,486

)

 

$

(4,696

)

 

(3)

 

$

(13,182

)

 

 

 

 

 

 

 

 

Income tax benefit

 

(565

)

 

 

 

 

 

 

 

(565

)

Interest expense, net

 

684

 

 

 

 

 

 

 

 

684

 

Depreciation and amortization

 

7,767

 

 

 

(491

)

 

(3)

 

 

7,276

 

Change in fair value of contingent consideration

 

1,646

 

 

 

 

 

 

 

 

1,646

 

Stock based compensation

 

3,350

 

 

 

 

 

 

 

 

3,350

 

Acquisition, restructuring and other items, net (1)

 

3,059

 

 

 

 

 

 

 

 

3,059

 

Adjusted EBITDA

$

7,455

 

 

$

(5,187

)

 

 

 

$

2,268

 

 

 

 

 

 

 

 

 

Per diluted share:

 

 

 

 

 

 

 

Adjusted EBITDA

$

0.19

 

 

$

(0.13

)

 

 

 

$

0.06

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended November 30, 2022.

 

(3) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA CONSOLIDATED INCOME STATEMENTS

Three Months Ended February 28, 2023

(in thousands, except per share data)

 

 

As Reported (1)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net sales

$

80,712

 

 

$

(7,502

)

 

(2)

 

$

73,210

 

Cost of sales (exclusive of intangible amortization)

 

40,208

 

 

 

(3,027

)

 

(2)

 

 

37,181

 

Gross profit

 

40,504

 

 

 

(4,475

)

 

 

 

 

36,029

 

% of net sales

 

50.2

%

 

 

 

 

 

 

49.2

%

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

6,852

 

 

 

(39

)

 

(2)

 

 

6,813

 

Sales and marketing

 

25,406

 

 

 

(11

)

 

(2)

 

 

25,395

 

General and administrative

 

8,839

 

 

 

6

 

 

(2)

 

 

8,845

 

Amortization of intangibles

 

4,739

 

 

 

(484

)

 

(2)

 

 

4,255

 

Change in fair value of contingent consideration

 

227

 

 

 

 

 

 

 

 

227

 

Acquisition, restructuring and other items, net

 

3,369

 

 

 

 

 

 

 

 

3,369

 

Total operating expenses

 

49,432

 

 

 

(528

)

 

 

 

 

48,904

 

Operating loss

 

(8,928

)

 

 

(3,947

)

 

 

 

 

(12,875

)

Interest expense, net

 

(736

)

 

 

 

 

 

 

 

(736

)

Other income (expense), net

 

 

 

 

 

 

 

 

 

 

Total other expense, net

 

(736

)

 

 

 

 

 

 

 

(736

)

Loss before income tax benefit

 

(9,664

)

 

 

(3,947

)

 

 

 

 

(13,611

)

Income tax benefit

 

(179

)

 

 

 

 

(3)

 

 

(179

)

Net loss

$

(9,485

)

 

$

(3,947

)

 

 

 

$

(13,432

)

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic

$

(0.24

)

 

 

 

 

 

$

(0.34

)

Diluted

$

(0.24

)

 

 

 

 

 

$

(0.34

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

 

39,509

 

 

 

 

 

 

 

39,509

 

Diluted

 

39,509

 

 

 

 

 

 

 

39,509

 

(1) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended February 28, 2023.

(2) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

(3) There are no adjustments for income tax expense or deferred taxes when considering valuation allowances on the Company's deferred taxes.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION

Three Months Ended February 28, 2023

(in thousands, except per share data)

 

Reconciliation of Net Loss to non-GAAP Adjusted Net Loss:

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(9,485

)

 

$

(3,947

)

 

(5)

 

$

(13,432

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

4,739

 

 

 

(484

)

 

(5)

 

 

4,255

 

Change in fair value of contingent consideration

 

227

 

 

 

 

 

 

 

 

227

 

Acquisition, restructuring and other items, net (1)

 

3,369

 

 

 

 

 

 

 

 

3,369

 

Tax effect of non-GAAP items (2)

 

127

 

 

 

1,019

 

 

 

 

 

1,146

 

Adjusted net loss

$

(1,023

)

 

$

(3,412

)

 

 

 

$

(4,435

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Loss Per Share:

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.24

)

 

$

(0.10

)

 

(5)

 

$

(0.34

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.12

 

 

 

(0.01

)

 

(5)

 

 

0.11

 

Change in fair value of contingent consideration

 

0.01

 

 

 

 

 

 

 

 

0.01

 

Acquisition, restructuring and other items, net (1)

 

0.08

 

 

 

 

 

 

 

 

0.08

 

Tax effect of non-GAAP items (2)

 

 

 

 

0.03

 

 

 

 

 

0.03

 

Adjusted diluted loss per share

$

(0.03

)

 

$

(0.08

)

 

 

 

$

(0.11

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

39,509

 

 

 

 

 

 

 

39,509

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended February 28, 2023.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

(4) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended February 28, 2023.

(5) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)

Three Months Ended February 28, 2023

(in thousands, except per share data)

 

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (2)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(9,485

)

 

$

(3,947

)

 

(3)

 

$

(13,432

)

 

 

 

 

 

 

 

 

Income tax benefit

 

(179

)

 

 

 

 

 

 

 

(179

)

Interest expense, net

 

736

 

 

 

 

 

 

 

 

736

 

Depreciation and amortization

 

7,787

 

 

 

(491

)

 

(3)

 

 

7,296

 

Change in fair value of contingent consideration

 

227

 

 

 

 

 

 

 

 

227

 

Stock based compensation

 

1,803

 

 

 

 

 

 

 

 

1,803

 

Acquisition, restructuring and other items, net (1)

 

3,369

 

 

 

 

 

 

 

 

3,369

 

Adjusted EBITDA

$

4,258

 

 

$

(4,438

)

 

 

 

$

(180

)

 

 

 

 

 

 

 

 

Per diluted share:

 

 

 

 

 

 

 

Adjusted EBITDA

$

0.11

 

 

$

(0.11

)

 

 

 

$

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended February 28, 2023.

(3) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA CONSOLIDATED INCOME STATEMENTS

Three Months Ended May 31, 2023

(in thousands, except per share data)

 

 

As Reported (1)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net sales

$

91,074

 

 

$

(8,755

)

 

(2)

 

$

82,319

 

Cost of sales (exclusive of intangible amortization)

 

44,715

 

 

 

(3,595

)

 

(2)

 

 

41,120

 

Gross profit

 

46,359

 

 

 

(5,160

)

 

 

 

 

41,199

 

% of net sales

 

50.9

%

 

 

 

 

 

 

50.0

%

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

7,860

 

 

 

(159

)

 

(2)

 

 

7,701

 

Sales and marketing

 

26,293

 

 

 

(21

)

 

(2)

 

 

26,272

 

General and administrative

 

10,228

 

 

 

 

 

(2)

 

 

10,228

 

Amortization of intangibles

 

4,406

 

 

 

(483

)

 

(2)

 

 

3,923

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

 

 

14,549

 

Change in fair value of contingent consideration

 

236

 

 

 

 

 

 

 

 

236

 

Acquisition, restructuring and other items, net

 

3,624

 

 

 

(368

)

 

(2)

 

 

3,256

 

Total operating expenses

 

67,196

 

 

 

(1,031

)

 

 

 

 

66,165

 

Operating loss

 

(20,837

)

 

 

(4,129

)

 

 

 

 

(24,966

)

Interest expense, net

 

(901

)

 

 

 

 

 

 

 

(901

)

Other expense, net

 

(127

)

 

 

 

 

 

 

 

(127

)

Total other expense, net

 

(1,028

)

 

 

 

 

 

 

 

(1,028

)

Loss before income tax benefit

 

(21,865

)

 

 

(4,129

)

 

 

 

 

(25,994

)

Income tax benefit

 

(398

)

 

 

 

 

(3)

 

 

(398

)

Net loss

$

(21,467

)

 

$

(4,129

)

 

 

 

$

(25,596

)

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic

$

(0.54

)

 

 

 

 

 

$

(0.65

)

Diluted

$

(0.54

)

 

 

 

 

 

$

(0.65

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

 

39,608

 

 

 

 

 

 

 

39,608

 

Diluted

 

39,608

 

 

 

 

 

 

 

39,608

 

(1) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended May 31, 2023.

(2) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

(3) There are no adjustments for income tax expense or deferred taxes when considering valuation allowances on the Company's deferred taxes.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION

Three Months Ended May 31, 2023

(in thousands, except per share data)

 

Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(21,467

)

 

$

(4,129

)

 

(5)

 

$

(25,596

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

4,406

 

 

 

(483

)

 

(5)

 

 

3,923

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

 

 

14,549

 

Change in fair value of contingent consideration

 

236

 

 

 

 

 

 

 

 

236

 

Acquisition, restructuring and other items, net (1)

 

3,624

 

 

 

(368

)

 

(5)

 

 

3,256

 

Tax effect of non-GAAP items (2)

 

(617

)

 

 

1,146

 

 

 

 

 

529

 

Adjusted net income (loss)

$

731

 

 

$

(3,834

)

 

 

 

$

(3,103

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Earnings (Loss) Per Share:

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.54

)

 

$

(0.11

)

 

(5)

 

$

(0.65

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.11

 

 

 

(0.01

)

 

(5)

 

 

0.10

 

Goodwill impairment

 

0.37

 

 

 

 

 

 

 

 

0.37

 

Change in fair value of contingent consideration

 

0.01

 

 

 

 

 

 

 

 

0.01

 

Acquisition, restructuring and other items, net (1)

 

0.09

 

 

 

(0.01

)

 

(5)

 

 

0.08

 

Tax effect of non-GAAP items (2)

 

(0.02

)

 

 

0.03

 

 

 

 

 

0.01

 

Adjusted diluted earnings (loss) per share

$

0.02

 

 

$

(0.10

)

 

 

 

$

(0.08

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

39,916

 

 

 

 

 

 

 

39,608

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2023.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

(4) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended May 31, 2023.

(5) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)

Three Months Ended May 31, 2023

(in thousands, except per share data)

 

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (2)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(21,467

)

 

$

(4,129

)

 

(3)

 

$

(25,596

)

 

 

 

 

 

 

 

 

Income tax benefit

 

(398

)

 

 

 

 

 

 

 

(398

)

Interest expense, net

 

901

 

 

 

 

 

 

 

 

901

 

Depreciation and amortization

 

7,506

 

 

 

(490

)

 

(3)

 

 

7,016

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

 

 

14,549

 

Change in fair value of contingent consideration

 

236

 

 

 

 

 

 

 

 

236

 

Stock based compensation

 

2,981

 

 

 

 

 

 

 

 

2,981

 

Acquisition, restructuring and other items, net (1)

 

3,624

 

 

 

(368

)

 

(3)

 

 

3,256

 

Adjusted EBITDA

$

7,932

 

 

$

(4,987

)

 

 

 

$

2,945

 

 

 

 

 

 

 

 

 

Per diluted share:

 

 

 

 

 

 

 

Adjusted EBITDA

$

0.20

 

 

$

(0.13

)

 

 

 

$

0.07

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the three months ended May 31, 2023.

(3) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA CONSOLIDATED INCOME STATEMENTS

As of May 31, 2023

(in thousands, except per share data)

 

 

As Reported (1)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net sales

$

338,752

 

 

$

(32,445

)

 

(2)

 

$

306,307

 

Cost of sales (exclusive of intangible amortization)

 

164,506

 

 

 

(12,914

)

 

(2)

 

 

151,592

 

Gross profit

 

174,246

 

 

 

(19,531

)

 

 

 

 

154,715

 

% of net sales

 

51.4

%

 

 

 

 

 

 

50.5

%

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

29,883

 

 

 

(326

)

 

(2)

 

 

29,557

 

Sales and marketing

 

104,249

 

 

 

(66

)

 

(2)

 

 

104,183

 

General and administrative

 

40,003

 

 

 

7

 

 

(2)

 

 

40,010

 

Amortization of intangibles

 

18,790

 

 

 

(1,933

)

 

(2)

 

 

16,857

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

 

 

14,549

 

Change in fair value of contingent consideration

 

2,320

 

 

 

 

 

 

 

 

2,320

 

Acquisition, restructuring and other items, net

 

15,633

 

 

 

(386

)

 

(2)

 

 

15,247

 

Total operating expenses

 

225,427

 

 

 

(2,704

)

 

 

 

 

222,723

 

Operating loss

 

(51,181

)

 

 

(16,827

)

 

 

 

 

(68,008

)

Interest expense, net

 

(2,702

)

 

 

 

 

 

 

 

(2,702

)

Other expense, net

 

(554

)

 

 

 

 

 

 

 

(554

)

Total other expense, net

 

(3,256

)

 

 

 

 

 

 

 

(3,256

)

Loss before income tax benefit

 

(54,437

)

 

 

(16,827

)

 

(3)

 

 

(71,264

)

Income tax benefit

 

(1,995

)

 

 

 

 

 

 

 

(1,995

)

Net loss

$

(52,442

)

 

$

(16,827

)

 

 

 

$

(69,269

)

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic

$

(1.33

)

 

 

 

 

 

$

(1.75

)

Diluted

$

(1.33

)

 

 

 

 

 

$

(1.75

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

 

39,480

 

 

 

 

 

 

 

39,480

 

Diluted

 

39,480

 

 

 

 

 

 

 

39,480

 

(1) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the year ended May 31, 2023.

(2) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

(3) There are no adjustments for income tax expense or deferred taxes when considering valuation allowances on the Company's deferred taxes.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION

As of May 31, 2023

(in thousands, except per share data)

 

Reconciliation of Net Loss to non-GAAP Adjusted Net Loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(52,442

)

 

$

(16,827

)

 

(5)

 

$

(69,269

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

18,790

 

 

 

(1,933

)

 

(5)

 

 

16,857

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

 

 

14,549

 

Change in fair value of contingent consideration

 

2,320

 

 

 

 

 

 

 

 

2,320

 

Acquisition, restructuring and other items, net (1)

 

15,633

 

 

 

(386

)

 

(5)

 

 

15,247

 

Tax effect of non-GAAP items (2)

 

(1,272

)

 

 

4,404

 

 

 

 

 

3,132

 

Adjusted net loss

$

(2,422

)

 

$

(14,742

)

 

 

 

$

(17,164

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Loss Per Share:

 

 

 

 

 

 

 

 

 

As Reported (4)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(1.33

)

 

$

(0.42

)

 

(5)

 

$

(1.75

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.48

 

 

 

(0.05

)

 

(5)

 

 

0.43

 

Goodwill impairment

 

0.37

 

 

 

 

 

 

 

 

0.37

 

Change in fair value of contingent consideration

 

0.06

 

 

 

 

 

 

 

 

0.06

 

Acquisition, restructuring and other items, net (1)

 

0.39

 

 

 

(0.01

)

 

(5)

 

 

0.38

 

Tax effect of non-GAAP items (2)

 

(0.03

)

 

 

0.11

 

 

 

 

 

0.08

 

Adjusted diluted loss per share

$

(0.06

)

 

$

(0.37

)

 

 

 

$

(0.43

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

39,480

 

 

 

 

 

 

 

39,480

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2023.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

(4) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the year ended May 31, 2023.

(5) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

PRO FORMA GAAP TO NON-GAAP RECONCILIATION (Continued)

As of May 31, 2023

(in thousands, except per share data)

 

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As Reported (2)

 

Pro Forma
Adjustments

 

Notes

 

As Adjusted

 

(unaudited)

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(52,442

)

 

$

(16,827

)

 

(3)

 

$

(69,269

)

 

 

 

 

 

 

 

 

Income tax benefit

 

(1,995

)

 

 

 

 

 

 

 

(1,995

)

Interest expense, net

 

2,702

 

 

 

 

 

 

 

 

2,702

 

Depreciation and amortization

 

30,681

 

 

 

(1,962

)

 

(3)

 

 

28,719

 

Goodwill impairment

 

14,549

 

 

 

 

 

 

 

 

14,549

 

Change in fair value of contingent consideration

 

2,320

 

 

 

 

 

 

 

 

2,320

 

Stock based compensation

 

11,158

 

 

 

 

 

 

 

 

11,158

 

Acquisition, restructuring and other items, net (1)

 

15,633

 

 

 

(386

)

 

(3)

 

 

15,247

 

Adjusted EBITDA

$

22,606

 

 

$

(19,175

)

 

 

 

$

3,431

 

 

 

 

 

 

 

 

 

Per diluted share:

 

 

 

 

 

 

 

Adjusted EBITDA

$

0.57

 

 

$

(0.49

)

 

 

 

$

0.09

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Reflects the Company's historical US GAAP consolidated financial statements, as reported, before pro forma adjustments related to the sale of the Business for the year ended May 31, 2023.

(3) Reflects the elimination of revenues and expenses representing the historical operating results of the Business.

 

Contacts

Investor:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408

Contacts

Investor:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408